Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Q4 2022 Earnings Call Transcript

Brian Adams: That’s a great question. We talked a lot about MedWise and I think it’s important for everybody that’s listening to understand that we use MedWise today in our PACE platform where we’re bringing pharmacy services to our PACE customers. We use MedWise to analyze those medication regimens for every single individual. So, thinking around bringing MedWise into some of those adjacent markets will not be us bringing pharmacy services, but in a different capacity. So, April and the strategy team and the commercialization team have really been looking at new ways for us to bring that to market and couple it with some of our existing paid solutions that we feel are very relevant for some of these adjacencies. I am excited over the coming quarters.

I think we’re going to have some good things to share with you on how we plan to effectively relaunch our MedWise go to market strategy. And so, I wouldn’t necessarily think of it in the same way that you think about . This is a platform that’s looking at multi-drug interactions, whereas some of these other products are it’s 1-to-1 drug. It’s a very simple process. I think we’re going to come at it from a very different perspective. And the value that we can ultimately provide by using this platform is significantly higher.

Jessica Tassan: Got it. And so the relaunch would be a 2023 relaunch with impact on 2024 bookings or 2024 revenue. Can you just kind of frame the timeline and that’s it from me, thanks?

Brian Adams: Yes, I think that’s a good timeframe in terms of expectation. We plan to be back in the market in the second half of the year with revenue being recognized starting in 2024.

Jessica Tassan: Thank you.

Operator: Thank you. I’m showing no further questions at this time. This concludes today’s conference call. Thank you for participating You may now disconnect.